Comparing the cost-effectiveness of Haloperidol, Risperidone and Olanzapine in the treatment of schizophrenia using the net-benefit regression approach
Download full text from publisher
CitationsCitations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
- Ifigeneia Mavranezouli, 2010. "A Review and Critique of Studies Reporting Utility Values for Schizophrenia-Related Health States," PharmacoEconomics, Springer, vol. 28(12), pages 1109-1121, December.
- Gregory Kruse & Bruce Wong & Mei Duh & Patrick Lefebvre & Marie-Hélène Lafeuille & John Fastenau, 2015. "Systematic Literature Review of the Methods Used to Compare Newer Second-Generation Agents for the Management of Schizophrenia: A focus on Health Technology Assessment," PharmacoEconomics, Springer, vol. 33(10), pages 1049-1067, October.
More about this item
NEP fieldsThis paper has been announced in the following NEP Reports:
StatisticsAccess and download statistics
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:ant:wpaper:2007012. See general information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Joeri Nys). General contact details of provider: http://edirc.repec.org/data/ftufsbe.html .
We have no references for this item. You can help adding them by using this form .